Affibody has announced a strategic collaboration with GE Healthcare to develop and commercialize Affibody-based PET imaging tracers, with initial focus on HER2 and PD-L1.
“The initiation of a strategic collaboration with GE Healthcare around PET imaging tracers reflects the commitment of Affibody to precision medicine and biomarker guided patient treatment. It also underlines the competitiveness of our technology and the value of the clinical data that has been generated with Affibody-based imaging agents,” said David Bejker, CEO of Affibody. “We believe that our collaboration with GE Healthcare to develop and commercialize these imaging agents will make a significant contribution to enhance the treatment of cancer patients globally”.
ABY-025
The Affibody technology is suited for the development of PET imaging tracers and ABY-025, a HER2-detecting Affibody-based PET imaging tracer, is currently in clinical development. ABY-025 provides a novel approach to diagnose global HER2-expression in metastatic breast cancer patients using PET imaging. Affibody is currently working together with academic institutions to explore the clinical utility of ABY-025 further.
PD-L1
The PD-L1 binding Affibody molecule is being developed as a diagnostic tool to improve selection and monitoring of patients with immuno-oncology treatments. The collaboration with GE Healthcare will accelerate studies through to a stage of clinical proof of concept, states the company.
A portfolio of molecular imaging agents for oncology
“We recognize that PET imaging plays a vital role in the development and use of cancer immunotherapies as it is a non-invasive way to measure patient response before, during and after treatment,” said Sanka Thiru, Head of Molecular Imaging Oncology, in GE Healthcare’s Pharmaceutical Diagnostics business. “We are partnering with companies like Affibody to build a portfolio of molecular imaging agents for oncology, focusing on those disease biomarkers that will help accelerate the development of the next generation of cancer treatments.”
Financial terms were not disclosed.
Photo of David Bejker, CEO, Affibody
